Vyxeos Liposomal is indicated for the treatment of adults with newly
diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML
with myelodysplasia-related changes (AML-MRC)1
previously untreated AML with a history of prior cytotoxic treatment or radiation therapy4,6
AML arising from previous MDS or MPN
De novo AML with MDS-related cytogenetic abnormality
De novo AML with multilineage dysplasia†
Up to 1 in 3‡ newly diagnosed patients may fall into these high-risk categories3,8 and could be eligible for treatment with Vyxeos Liposomal1,9
Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.
I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL
I AM A UK HEALTHCARE PROFESSIONAL
I AM A US HEALTHCARE PROFESSIONAL
I AM NOT A HEALTHCARE PROFESSIONAL
Please note that this information is intended for healthcare professionals in the UK
Please note that this information is intended for healthcare professionals in the US only
For more information:
By clicking here you will be taken to the European Medicines Agency’s external website
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.